[Summary] A total of 165 type 2 diabetic patients were divided into two groups with pigmented pretibial pathes(PPP group) and no PPP( NPPP group). 50 subjects with normal glucose regulation were used as a control group(NGR group). The records of sex, age, diabetes duration, body mass index( BMI), systolic blood pressure (SBP), diastolic blood pressure, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, fasting blood glucose(FBG), 2 h postpradial plasma glucose(2hPG), triglyceride(TG), total cholesterol, HbA1C , retinol binding protein 4(RBP4), cystatin C(Cys C)were analyzed. The results showed that BMI,FBG, 2hPG, TG, and Cys C levels in NPPP group were higher than those in NGR group(all P<0. 01). The levels of BMI, SBP, FBG, 2hPG, TG, Cys C, and RBP4 in PPP group were higher than those in NGR group(P<0. 01 or P<0. 05), while diabetes duration, FBG, 2hPG, HbA1C , Cys C, and RBP4 in PPP group were higher than those in NPPP group ( P <0. 01). Pearson correlation analysis revealed that serum RBP4 and Cys C were in linear positive correlation(r=0. 77, P< 0. 01). The areas under receiver operating characteristic curve of RBP4 and Cys C were 0. 81 and 0. 78, respectively(P<0. 01). The results of binary logistic regression analysis showed that diabetes duration, HbA1C , RBP4 were related to PPP(r=0. 37, 0. 26, 0. 22, P<0. 05 or P<0. 01).

Objective To explore the correlation between serum complement C1q and microalbuminuria (MAU) in patients with type 2 diabetes mellitus (T2DM). Methods Two hundred and thirty patients with T2DM from January 2017 to July 2018 were selected. The patients were divided into 3 groups according to the MAU: group A (100 patients with MAU≤30 mg/L), group B (80 patients with 30 mg/L ＜ MAU ≤ 300 mg/L) and group C (50 patients with MAU ＞300 mg/L). The clinical data were recorded and serum complement C1q was measured by immunoturbidimetry. The homeostatic model assessment C-peptide resistance index (HOMA-CR) was calculated. The correlation was analyzed by Spearman correlation analysis, and multivariate Logistic regression analysis was performed with MAU ＞300 mg/L as dependent variable. Results The complement C1q in group C was significantly higher than that in group A and group B: (198.72 ± 43.25) mg/L vs. (173.42 ± 29.36) and (181.57 ± 35.79) mg/L, and there was statistical difference (P＜0.05). Spearman correlation analysis result showed that serum complement C1q had positive correlation with body mass index (BMI), fasting C-peptide (FCP), HOMA-CR and MAU in patients with T2DM (r = 0.22, 0.26, 0.31 and 0.38; P＜0.05). Multivariate Logistic regression analysis result showed that course of disease, glycosylated hemoglobin A1c (HbA1c) and complement C1q were the independent risk factor of MAU＞300 mg/L in patients with T2DM (P＜0.01). Conclusions In patients with T2DM, serum complement C1q has positive correlation with MAU, and it is the independent risk factor of MAU＞300 mg/L. The serum complement C1q may be one of the indicators of large amount of MAU.

Objective To investigate the effect of insulin pump combined with dipeptidyl peptidase-Ⅳ (DPP-Ⅳ) inhibitor on the treatment of newly diagnosed type 2 diabetes mellitus (T2 DM). Methods Totally 51 newly diagnosed patients with T2 DM were randomly divided into experimental group (insulin pump combined with DPP-Ⅳ inhibitor) and control group (insulin pump alone). After 15 days of treatment, the clinical effect was compared between two groups. Results After treatment, the blood sugar related indexes in both groups significantly improved (P ＜ 0. 05), and the blood sugar control of the experimental group was significantly better than that of the control group (P ＜ 0. 05). The pancreatic β cell function index, area under curve of C-peptide and insulin resistance index in the experimental group were significantly better than those in the control group (P ＜0. 05). The dosage of insulin, the ratio of patients with blood sugar reaching the standard completely, the time of blood sugar reaching the standard and the increase value of body mass in the experimental group were significantly better than those in the control group (P ＜ 0. 01). The incidence rate of hypoglycemia was 8. 00％ (2/26) in the experimental group and 12. 00％ (3/25) in the control group, and there was no significant difference between the two groups (P＞ 0. 05). During the treatment, no severe hypoglycemic events and liver and kidney function damage occurred in both groups. Conclusion Insulin pump combined with DPP-Ⅳ inhibitor is effective in the treatment of newly diagnosed T2 DM, which can effectively control blood sugar, reduce insulin resistance and weight gain.